Latest Octreotide Stories

2010-06-13 23:01:00

NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally.

2010-04-30 08:52:04

Octreotide provides benefits for both the liver and kidney in patients with ADPKD.

2009-05-28 00:28:00

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer - New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen - Phase II data show potential of Glivec(R)...

2009-01-27 15:15:00

LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com.

2009-01-13 17:47:00

- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs) EAST HANOVER, N.J., Jan.

2009-01-05 15:50:00

Company to Host Conference Call January 6, 2009 at 8:30 a.m. EST LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has entered into a definitive merger agreement under which Endo Pharmaceuticals Holdings, Inc.

2009-01-05 15:29:00

Acquisition Adds Marketed Products and Specialty Sales Force in Urology and Endocrinology, Novel Drug-Delivery Technology Combined Pipeline to Include Nine FDA-Approved Therapeutics Conference Call Scheduled for Today at 5:30 pm EST CHADDS FORD, Pa. and LEXINGTON, Mass., Jan.

2008-10-01 15:00:50

Ambrilia Biopharma Inc. (TSX: AMB) today reported positive 24-week extension Phase III ("Study 302") top line results for its proprietary prolonged-release formulation of octreotide C2L. Overall, the results support the safety of C2L over an additional period of 6 months.

2008-09-30 09:00:18

LEXINGTON, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced the initiation of a Phase III clinical trial of the Company's novel octreotide implant for acromegaly.

Word of the Day
  • The word or words serving to define another word or expression, as in a dictionary entry.
The word 'definiens' comes from the Latin word 'definire', 'to define'.